The Center for Biosimilars® recaps the top news for the week of August 20, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 20.
Number 5: A Japanese company has launched Celltrion’s trastuzumab biosimilar in Japan, but the product will only be sold to treat HER2-positive gastric cancers.
Number 4: The FDA has granted priority review for Alexion’s proposed long-acting C5 complement inhibitor that could help stave off biosimilar competition for the Soliris market.
Number 3: A new paper in BioDrugs argues that phase 3 studies may no longer be necessary for biosimilars.
Number 2: The United Kingdom’s National Institute for Health and Care Excellence says that it does not recommend Perjeta for routine use after surgery in patients with breast cancer, even though using the drug in combination with biosimilar trastuzumab could reduce the total cost of treatment.
Number 1: Pfizer’s proposed adalimumab biosimilar demonstrated similar efficacy, safety, and immunogenicity profiles to the reference Humira at 26 weeks of treatment in patients with rheumatoid arthritis.
Finally, last week, our e-newsletter asked whether you think that the United States’ patent system needs reform to prevent abuse by drug makers.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.